Data as of . Holdings from the fund’s latest public SEC N-PORT filing; overlap and active share computed by ETFIQ against the IVV and QQQM books; returns from Tiingo end-of-day prices with distributions reinvested.
ARKG · ARK Genomic Revolution ETF
ARK · Themes desk
Open the live card on ETFIQBy weight, 4% of ARKG's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 59% of the fund across 33 positions, as filed for Sep 4, 2026. Over the year to Sep 4, 2026 the fund returned +89.3% with distributions reinvested against +20.0% for the S&P 500, so a holder was ahead by 69.4 pts. It sits 57.8% below its all-time high of Jan 20, 2021.
| Theme (ETFIQ, editorial) | Genomics and biotech innovation |
|---|---|
| Launched | Oct 31, 2014 |
| Already in the S&P 500, by weight (ETFIQ) | 3.9% |
| Active share vs the S&P 500 (ETFIQ) | 98.5% |
| Already in the Nasdaq-100, by weight (ETFIQ) | 0.0% |
| Active share vs the Nasdaq-100 (ETFIQ) | 100.0% |
| Top ten holdings weight | 58.9% |
| Holdings | 33 |
| Net assets (latest filing) | $1,236M |
| Holdings as of (SEC N-PORT) | Sep 4, 2026 |
| Top holdings | 10X GENOMICS INC-CLASS A 9.5%, TWIST BIOSCIENCE CORP 8.3%, TEMPUS AI INC-CL A 8.1%, CRISPR THERAPEUTICS AG 6.0%, PERSONALIS INC 5.8%, ABSCI CORP 4.8%, GUARDANT HEALTH INC 4.3%, ILLUMINA INC 4.2%, NATERA INC 4.1%, ELI LILLY & CO 3.9% |
| 3 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +41.1% / +4.7% / +36.4 pts / +39.0 pts |
| 6 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +67.6% / +15.2% / +52.5 pts / +47.5 pts |
| 1 year: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +89.3% / +20.0% / +69.4 pts / +63.7 pts |
| 3 years: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +47.3% / +78.0% / −30.7 pts / −46.2 pts |
| since launch: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +150.7% / +365.3% / −214.7 pts / −525.3 pts |
| Below its all-time high (ETFIQ) | −57.8% |
| Expense ratio (prospectus XBRL) | 0.75% |
| Fee for the part that differs from the S&P 500, active expense ratio (ETFIQ) | 0.76% |
| Closest funds by holdings overlap | GNOM 37%, ARKK 27%, HELX 25%, EKG 24%, HTEC 16% |
Questions people ask
- How much of ARKG is already in the S&P 500?
- By its holdings filed for Sep 4, 2026, 4% of ARKG by weight is stocks the S&P 500 already holds. Its active share against the index is 98%, so that share is the part doing something different.
- What does ARKG hold?
- 33 positions as filed for Sep 4, 2026, with the top ten at 59% of the fund. The largest are 10X GENOMICS INC-CLASS A at 9.5%, TWIST BIOSCIENCE CORP at 8.3%, TEMPUS AI INC-CL A at 8.1%.
- Has ARKG beaten the S&P 500?
- Over the year to Sep 4, 2026 ARKG returned +89.3% with distributions reinvested, against +20.0% for the S&P 500, so it finished ahead of the index by 69.4 points.
- What does ARKG cost?
- The prospectus expense ratio is 0.75% a year. Because 98% of the fund differs from the S&P 500, the fee on that differing part works out at 0.76%.
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Funds near this one
Put this on your own page
The difference bar for ARKG, redrawn every trading night. Free to use with the credit link; paste these two lines into any page or newsletter.
<a href="https://etfiq.com/funds/ARKG.html"><img src="https://etfiq.com/embed/themes/ARKG.svg" alt="ARKG difference bar, ETFIQ" width="640"></a>
<p><a href="https://etfiq.com/funds/ARKG.html">ARKG difference bar, updated daily by ETFIQ</a></p>Cite this page. ETFIQ, ARKG on the themes desk, data as of Sep 4, 2026. https://etfiq.com/funds/ARKG.html Free to use with attribution; the underlying files are at Open data.
ETFIQ is an independent publisher of exchange-traded fund data. It is not a fund issuer, broker-dealer or investment adviser, and it makes no recommendations; sort orders and figures are stated arithmetic on published data. Standards · How to read this desk